Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data on each of its clinical-stage anticancer compounds at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) being held April 12-16 in San Diego, CA. Sunesis has built a portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell cycle and survival signaling.

Data from non-clinical studies of SNS-595, SNS-032 and SNS-314 will be presented in five posters and one oral presentation during the AACR Meeting. New insights on the mechanism of action and anticancer activity of SNS-595, Sunesis' lead compound, will be featured on Monday, April 14, 2008. SNS-595 is a novel naphthyridine analog structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 both selectively intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b combination clinical trial with cytarabine in relapsed/refractory acute myeloid leukemia are both ongoing.

SNS-595 Poster Presentations

Monday, April 14, 2008

-- SNS-595 is a potent anti-tumor agent that has a dual mechanism of

action: DNA intercalation and site-selective topoisomerase II poisoning

Session: Stress Responses

Abstract #1860

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

-- Sensitivity to SNS-595 is related to activation of double strand DNA


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... 5 Diplomat Specialty Pharmacy,announced today that their ... is now live and being utilized to manage,their ... eNAV(TM) as a,disease management tool for all disease ... Crohn,s Disease,and Chronic Kidney Disease., "Our current ...
... of Insulin Doses Administered Were Delivered Within Pre-Determined ... Guidelines and Standard Dosing Limitations, ... the dose accuracy of the SoloSTAR(R) disposable insulin pen,prefilled ... glulisine [rDNA origin] injection), found the pens,accurately delivered all ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir Choroomi, is ... is one of the most powerful whitening treatments available today, ... light-assisted treatment uses a prescription-strength gel that can penetrate quickly ... up stains that are in both the enamel and the ... and tobacco stains. , About Dr. Amir Choroomi, Expert ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is introducing its newest solution in an ... Enhance Quality. , The webinar will be held twice ... again at 2 PM ET. For more information or ... or call 866.799.2655. , In an environment of ...
(Date:7/25/2014)... quickly after Manchester research , Clinical judgement, combined ... arrival, is effective in reducing unnecessary hospital admissions ... findings of a research group in Manchester, published ... a huge difference to a large number of ... for emergency hospital admission. In Manchester, the incidence ...
(Date:7/25/2014)... prevents obesity could be on the horizon. Bacteria ... inhibit weight gain, insulin resistance and other adverse ... University investigators have discovered. , "Of course it,s ... senior investigator Sean Davies, Ph.D., assistant professor of ... negative consequences of obesity in mice, even though ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
... a good way of relieving stress and providing the mind ... that exercise can lift a person's spirits// , and there ... clinical depression. Exercise helps in the reduction of anger, fatigue ... walking or running has become popular among health freaks. It ...
... some researchers found that milk chocolate containing caffeine has ... having better reaction times. ,Hence, chocolate ... others. ,Adding value to the above study, ... Professer, Dr. Bryan Raudenbush, Wheeling Jesuit University has done ...
... regulate breathing abnormalities of premature babies. Artificial breathing equipments ... with caffeine therapy and found to have a lower incidence ... , ,About 2,000 premature babies, who weighed below 1,250 grams, ... were studied. , ,More than 47 per ...
... direct talks with Prime Minister Manmohan Singh and decided to ... meeting with the medicos during which he told them that ... which would see a huge growth in the educational opportunities ... Prime Minister assured the medicos that they need not be ...
... A research conducted by the King’s Collage London, analysed health reports ... war in 2003 with those who took part// in the 1991 ... ,The study findings that are published in The Lancet ... War Syndrome" in British male armed forces personnel deployed to the ...
Cached Medicine News:
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: